Avoid common mistakes on your manuscript.
The journal LUNG has been in continuous publication since 1903. Established as a German-language publication, LUNG transformed to an exclusively English-language journal in the 1970s. The journal continues to enjoy an international readership as well as manuscript submissions from authors worldwide.
The year 2020 marked the retirement of Editor-in-Chief F. Dennis McCool, MD, under whose 17-year stewardship LUNG continued to grow, flourish, and firmly establish itself as a leading journal in the space of pulmonary medicine. Manuscript submissions to the journal have steadily increased in quantity and quality, thus resulting in our current acceptance rate of submitted manuscripts of under 15%. Although full-year data were not yet available at the time of this writing, journal article downloads in 2020 were on track to far exceed the 117,349 article downloads of 2019.
At the beginning of 2020 I had the honor of assuming the role of Editor-in-Chief of LUNG. The journal and I owe Dr. McCool a great debt for his many years of outstanding service, and for facilitating a smooth transition for me and other new members of the editorial team. A positive aspect of any change in leadership is that it allows for evaluation, reflection, and establishment of new strategies for ongoing success. To that end, among my first actions as Editor-in-Chief was to bring on an outstanding group of Associate Editors who comprise a truly international body of expertise in the various fields within pulmonary and critical care medicine. We have no doubt that the intellectual energy, creativity, and enthusiasm of this new group of renowned clinicians and scientists will continue to move the journal forward in a positive trajectory.
In terms of specific goals, we aim to publish at least one State-of-the-Art review article in each edition of the journal. State-of-the-Art reviews are comprehensive reviews on a specific topic written by experts in the field. Such articles are typically invited, however, outstanding, unsolicited reviews will be considered as well. In 2020, we were pleased to publish 15 State-of-the-Art reviews [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] within our six issues. In keeping with our goal of enhancing the critical care content within the journal, publications in 2020 included a State-of-the-Art review of lung ultrasound in the assessment and management of acute respiratory failure [1], as well as articles reporting vaping-induced acute respiratory failure [16]; the use of diaphragmatic ultrasound to facilitate liberation from mechanical ventilation [17]; intensive care unit (ICU) utilization practices for patients with COPD [18]; biomarkers in sepsis-associated acute lung injury [19]; and optimal ventilator management during extracorporeal membrane oxygenation (ECMO) [20].
The year 2020 witnessed a pandemic of COVID-19-related manuscript submissions to medical journals, and LUNG was not immune to the onslaught. As of December 31, 2020, a National Library of Medicine (PubMed) search of the term “COVID-19” yielded over 88,000 articles. We at LUNG were very selective in our acceptance of SARS-CoV-2-related manuscripts, since most submissions were retrospective, descriptive series of patients, often small in number and not contributing to the extant published literature. Four notable exceptions included the first study reporting an association of COVID-19 outcome with levels of surfactant protein D [21]; a study of the effect of COVID-19 on patients with sarcoidosis [22]; a State-of-the-Art review on the relevance of the ACE-2 receptor in SARS-CoV-2 infection [14]; and an editorial examining chronic cough as a residual effect of the illness [23].
We were delighted that in 2020, pediatric pulmonology was well represented within the pages of our journal. In addition to featuring a State-of-the Art review on the evaluation and management of children with obstructive sleep apnea syndrome (OSAS) [5], we published studies on cystic fibrosis (CF) [24,25,26] and non-CF-related pediatric topics [27,28,29]. We remain eager to publish high-quality articles in the field of pediatric respiratory medicine, and encourage authors working in this area to consider submission of their highest quality work to LUNG.
As would be expected, studies in obstructive airways disease comprised a large portion of our published articles. New aspects of pathophysiology and diagnosis of asthma were described in both clinical and basic investigations [30,31,32,33,34,35,36,37]. In keeping with historical precedent, COPD-related research played a prominent role in each issue of the journal [18, 38,39,40,41,42,43,44,45,46,47,48,49,50].
Pulmonary arterial hypertension (PAH) continues to be among the most active fields of inquiry in respiratory medicine. In addition to a State-of-the-Art review of treatment guidelines for PAH [7], we published a number of studies exploring clinical aspects of this condition [51,52,53,54,55,56].
Fueled by the recent availability of therapeutic options, investigative work in the areas of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) proceeds with enthusiasm. Reflecting the emergence of information in this field, LUNG featured three relevant State-of-the-Art reviews [6, 8, 10], as well as an eclectic selection of clinical studies [56,57,58,59,60,61,62].
The greatest amount of current research in pulmonary medicine is undoubtedly committed to the study of lung cancer. New discoveries and insights are emerging at a remarkable rate. Participating in the dissemination of this plethora of information, LUNG published a State-of-the-Art review on new developments in the management of non-small cell lung cancer [15] as well as a collection of articles examining lung cancer epidemiology, screening, multidisciplinary management, surgical intervention, prognosis, and outcomes [63,64,65,66,67,68,69,70,71,72,73,74].
Emerging as one of the most prolific areas of investigation in pulmonary medicine is the field of sleep disorders. In 2020, we published two articles on pediatric obstructive sleep apnea syndrome (OSAS) [5, 27], including a State-of-the-Art review on the evaluation and management of children with OSAS [5]. Studies in adult OSAS included therapy [79], adherence [76], risk of occupational injury [78], and possible associated biomarkers [75, 77, 80].
LUNG has historically given prominent attention to the important topic of cough. Cough is the most common complaint for which persons in the United States seek medical attention [81]. Thankfully, the last decade has seen a great increase in cough-related research which has led to multiple antitussive drug development programs currently underway [9]. Cough-related articles featured in 2020 included State-of-the-Art reviews on the placebo effect in cough clinical trials [2], the role of excipients in antitussive preparations [11], and an update on the status of chronic cough in China [3]. Other topics covered were drug-associated cough [82], therapeutic strategies for chronic cough [79, 83], the role of cough assessment in monitoring patients with asthma [36] and COPD [47], the question of whether there will be an emergence of a post-COVID-19 chronic cough [23], and abstracts from the Seventh American Cough Conference [84].
The field of lung transplantation was addressed in a State-of-the-Art review of infectious complications in this patient population [13], while other articles examined post-transplant bronchiolitis obliterans syndrome in CF patients [85] as well as cytomegalovirus reactivation in lung transplant recipients [86].
Interventional pulmonology and thoracic surgery received deserved attention, with multiple articles addressing the evolving field of bronchoscopic lung volume reduction surgery [87,88,89], as well as percutaneous interventions [59, 90], and surgical procedures [12, 74, 91]. Other contributions addressed aspects of respiratory physiology [29, 89, 92], pulmonary rehabilitation [93, 94], tuberculosis [95], non-tuberculous mycobacterial infection [96], and World Trade Center-related lung disease [97].
Basic science provides the foundation from which clinical progress results. In 2020, we were pleased to publish several quality preclinical trials in the area of acute lung injury [98,99,100,101] as well as studies pertaining to asthma [32], lung cancer [66], cystic fibrosis [102, 103], pulmonary fibrosis [104], and mechanisms of pulmonary drug delivery [105].
The year 2020 was an exciting and productive one at LUNG. We look forward to ongoing progress at our journal. To achieve that goal, we will continue to rely on our colleagues worldwide, working at the bedside and in the laboratory, to contribute their quality work to LUNG.
References
Islam M, Levitus M, Eisen L, Shiloh AL, Fein D (2020) Lung ultrasound for the diagnosis and management of acute respiratory failure. Lung 198(1):1–11
Eccles R (2020) The powerful placebo effect in cough: relevance to treatment and clinical trials. Lung 198(1):13–21
Lai K, Long L (2020) Current status and future directions of chronic cough in China. Lung 198(1):23–29
Haramati A, Haramati LB (2020) Imaging of chronic thromboembolic disease. Lung 198(2):245–255
Bitners AC, Arens R (2020) Evaluation and management of children with obstructive sleep apnea syndrome. Lung 198(2):257–270
Varone F, Iovene B, Sgalla G, Calvello M, Calabrese A, Larici AR, Richeldi L (2020) Fibrotic hypersensitivity pneumonitis: diagnosis and management. Lung 198(3):429–440
Vazquez ZGS, Klinger JR (2020) Guidelines for the treatment of pulmonary arterial hypertension. Lung 198(4):581–596
Gibson CD, Kugler MC, Deshwal H, Munger JS, Condos R (2020) Advances in targeted therapy for progressive fibrosing interstitial lung disease. Lung 198(4):597–608
Dicpinigaitis PV, McGarvey LP, Canning BJ (2020) P2X3-receptor antagonists as potential antitussives: summary of current clinical trials in chronic cough. Lung 198(4):609–616
Jeganathan N, Sathananthan M (2020) Connective tissue disease-related interstitial lung disease: prevalence, patterns, predictors, prognosis, and treatment. Lung 198(5):735–759
Eccles R (2020) What is the role of over 100 excipients in over the counter (OTC) cough medicines? Lung 198(5):727–734
Tanner TG, Colvin MO (2020) Pulmonary complications of cardiac surgery. Lung 198(6):889–896
Trachuk P, Bartash R, Abbasi M, Keene A (2020) Infectious complications in lung transplant recipients. Lung 198(6):879–887
Scialo F, Daniele A, Amato F et al (2020) ACE2: the major cell entry receptor for SARS-CoV-2. Lung 198(6):867–877
Alexander M, Kim SY, Cheng H (2020) Update 2020: management of non-small cell lung cancer. Lung 198(6):897–907
Dicpinigaitis PV, Trachuk P, Fakier F et al (2020) Vaping-associated acute respiratory failure due to acute lipoid pneumonia. Lung 198(1):31–33
McCool FD, Oyieng’o DO, Koo P (2020) The utility of diaphragm ultrasound in reducing time to extubation. Lung 198(3):499–505
Matthews KS, Goel NN, Vargas-Torres C et al (2020) A cross-sectional study of hospital performance on ICU utilization practices for patients with chronic obstructive pulmonary disease. Lung 198(4):637–644
Li G, Zhang L, Han N et al (2020) Increased Th17 and Th22 cell percentages predict acute lung injury in patients with sepsis. Lung 198(4):687–693
Gupta E, Awsare B, Hiroshi H et al (2020) Don’t drive blind: driving pressure to optimize ventilator management in ECMO. Lung 198(5):785–792
Kerget B, Kerget F, Kocak AO et al (2020) Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19? Lung 198(5):777–784
Morgenthau AS, Levin MA, Freeman R et al (2020) Moderate or severe impairment in pulmonary function is associated with mortality in sarcoidosis patients infected with SARS-CoV-2. Lung 198(5):771–775
Dicpinigaitis PV, Canning BJ (2020) Is there (will there be) a post-COVID-19 chronic cough? Lung 198(6):863–865
Procianoy EDFA, de Abreu e Silva FA, Marostica PJC et al (2020) Chloride conductance, nasal potential difference and cystic fibrosis pathophysiology. Lung 198(1):151–156
Kasi AS, Wee CP, Keens TG et al (2020) Abnormal lung clearance index in cystic fibrosis screen positive, inconclusive diagnosis (CFSPID) children with otherwise normal FEV1. Lung 198(1):163–167
Sagwal S, Chauhan A, Kaur J et al (2020) Association of serum TGF-β1 levels with different clinical phenotypes of cystic fibrosis exacerbation. Lung 198(2):377–383
Shafiek H, Evangelisti M, Abd-elwahab NH et al (2020) Obstructive sleep apnea in school-aged children presented with nocturnal enuresis. Lung 198(1):187–194
Collaro AJ, Chang AB, Marchant JM et al (2020) Culturally appropriate outreach specialist respiratory medical care improves the lung function of children in regional and remote Queensland. Lung 198(2):361–369
Kotwal N, Shukla PJ, Perez GF (2020) Peak cough flow in children with neuromuscular disorders. Lung 198(2):371–375
Ramonell RP, Iftikhar IH (2020) Effect of anti-IL5, anti-IL5R, anti-IL13 therapy on asthma exacerbations: a network meta-analysis. Lung 198(1):95–103
Matloubi M, Ranjbar M, Assarehzadegan M-A et al (2020) The impact of interleukin (IL)-33 gene polymorphisms and environmental factors on risk of asthma in the Iranian population. Lung 198(1):105–112
Whitehead GS, Hussain S, Fannin R et al (2020) TLR5 activation exacerbates airway inflammation in asthma. Lung 198(2):289–298
Huang J, Liu J, Xian Y et al (2020) Elevated circulating CD4+ CD25+ CD127-/low regulatory T cells in patients with non-asthmatic eosinophilic bronchitis. Lung 198(3):491–497
Voelker D, Almodallal Y, Scrodin MD et al (2020) Newer biological agents in the treatment of severe asthma: real-world results from a tertiary referral center. Lung 198(4):653–659
Ventaggiato L, Perruzza M, Refini RM et al (2020) Mepolizumab and benralizumab in severe eosinophilic asthma: preliminary results of a proteomic study. Lung 198(5):761–765
Faruqi S, Sykes DL, Crooks MG et al (2020) Objective assessment of cough: an early marker of response to biological therapies in asthma? Lung 198(5):767–770
Alzghoul BN, Reddy R, Chizinga M et al (2020) Pulmonary embolism in acute asthma exacerbation: clinical characteristics, prediction model and hospital outcomes. Lung 198(4):661–669
Hallowell RW, Schwartzstein R, O’Donnell CR et al (2020) Controlled delivery of 80 mg aerosol furosemide does not achieve consistent dyspnea relief in patients. Lung 198(1):113–120
Meservey AJ, Burton MC, Priest J et al (2020) Risk of readmission and mortality following hospitalization with hypercapnic respiratory failure. Lung 198(1):121–134
Rodrigues A, Mara de Oliveira J, Furlanetto KC et al (2020) Are the effects of high-intensity exercise training different in patients with COPD versus COPD+asthma overlap? Lung 198(1):135–141
Tran D, Lim M, Vogrin S et al (2020) Point of care portable spirometry in the diagnosis and treatment of inpatients with chronic obstructive pulmonary disease. Lung 198(1):143–150
Harlander M, Lestan D, Turel M (2020) Chitotriosidase activity in plasma and COPD exacerbations. Lung 198(2):299–306
Kerget B, Afsin DE, Kerget F et al (2020) Is Metrnl an adipokine involved in the anti-inflammatory response to acute exacerbations of COPD? Lung 198(2):307–314
Kardos P, Vogelmeier CF, Worth H et al (2020) COPD assessment test changes from baseline correlate with COPD exacerbations: a longitudinal analysis of the DACCORD observational study. Lung 198(3):507–514
Ghobadi H, Hosseini N, Aslani MR (2020) Correlations between serum decoy receptor 3 and airflow limitation and quality of life in male patients with stable stage and acute exacerbation of COPD. Lung 198(3):515–523
Upadhyay J, Trivedi N, Lal A (2020) Risk of future type 2 diabetes mellitus in patients developing steroid-induced hyperglycemia during hospitalization for chronic obstructive pulmonary disease exacerbation. Lung 198(3):525–533
Cho PSP, Fletcher HV, Turner RD et al (2020) The relationship between cough reflex sensitivity and exacerbation frequency in chronic obstructive pulmonary disease. Lung 198(4):617–628
De Weger WW, Klooster K, ten Hacken NH et al (2020) Determining static hyperinflation in patients with severe emphysema: relation between lung function parameters and patient-related outcomes. Lung 198(4):629–636
Huang S-J, Ding Z-N, Xiang H-X et al (2020) Association between serum S100A8/S100A9 heterodimer and pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease. Lung 198(4):645–652
Saito Z, Yoshida M, Kojima A et al (2020) Benefits and risks of inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease classified by blood eosinophil counts. Lung 198(6):925–931
Kimmig LM, Liao C, Bag R (2020) Ambulatory transition from parenteral prostanoid to inhaled treprostinil in patients with pulmonary arterial hypertension. Lung 198(1):53–58
Rashid F, Parvizi R, Bilejani E et al (2020) Evaluation of the incidence of chronic thromboembolic pulmonary hypertension 1 year after first episode of acute pulmonary embolism: a cohort study. Lung 198(1):59–64
Wronski SL, Mordin M, Kelley K et al (2020) The role of noninvasive endpoints in predicting long-term outcomes in pulmonary arterial hypertension. Lung 198(1):65–86
Tooba R, Almoushref A, Tonelli AR (2020) Is there value in repeating inhaled nitric oxide vasoreactivity tests in patients with pulmonary arterial hypertension? Lung 198(1):87–94
Schoenberg NC, Argula RG, Klings ES et al (2020) Prevalence and mortality of pulmonary hypertension in ESRD: a systematic review and meta-analysis. Lung 198(3):535–545
Sobiecka M, Lewandowska K, Kober J et al (2020) Can a new scoring system improve prediction of pulmonary hypertension in newly recognized interstitial lung diseases? Lung 198(3):547–554
Hosein KS, Sergiacomi G, Zompatori M et al (2020) The CALIPER-revised version of the composite physiologic index is a better predictor of survival in IPF than the original version. Lung 198(1):169–172
Moll SA, Wiertz IA, Vorselaars ADM et al (2020) Change in serum biomarker CA 15-3 as an early predictor of response to treatment and survival in hypersensitivity pneumonitis. Lung 198(2):385–393
Adams TN, Batra K, Silhan L et al (2020) Utility of bronchoalveolar lavage and transbronchial biopsy in patients with interstitial lung disease. Lung 198(5):803–810
Gibson CD, Bhatt A, Deshwal H et al (2020) Comparison of clinical measures among interstitial lung disease (ILD) patients with usual interstitial pneumonia (UIP) patterns on high-resolution computed tomography. Lung 198(5):811–819
Zinellu A, Paliogiannis P, Sotgiu E et al (2020) Blood cell count derived inflammation indexes in patients with idiopathic pulmonary fibrosis. Lung 198(5):821–827
Ritzenthaler JD, Zhang M, Torres-Gonzalez E et al (2020) The integrin inhibitor cilengitide and bleomycin-induced pulmonary fibrosis. Lung 198(6):947–955
Galvez-Nino M, Ruiz R, Pinto JA et al (2020) Lung cancer in the young. Lung 198(1):195–200
Kasmann L, Abdo R, Eze C et al (2020) External validation of a survival score for limited-stage small cell lung cancer patients treated with chemoradiotherapy. Lung 198(1):201–206
Wang C, Jin S, Xu S et al (2020) High systemic immune-inflammation index (SII) represents an unfavorable prognostic factor for small cell lung cancer treated with etoposide and platinum-based chemotherapy. Lung 198(2):405–414
Hu B, Li X, Chen L et al (2020) High expression of CARM1 inhibits lung cancer progression by targeting TP53 by regulating CTNNB1. Lung 198(2):415–422
Adachi Y, Matsumoto K, Enomoto T (2020) Lung cancer in young patients: the importance of assessing driver mutations and treatment strategies [letter]. Lung 198(2):425–426
Thein KZ, Quick DP, Htut TW et al (2020) Impact of primary ambulatory thromboprophylaxis (PATP) with low-molecular weight heparins (LMWHs) on survival in patients with lung cancer receiving chemotherapy. Lung 198(3):575–579
Yilmaz A, Tekin SB, Bilici M et al (2020) The significance of controlling nutritional status (CONUT) score as a novel prognostic parameter in small cell lung cancer. Lung 198(4):695–704
Ponvilawan B, Charoenngam N, Rujirachun P et al (2020) Chronic hepatitis C virus infection is associated with an increased risk of lung cancer: a systematic review and meta-analysis. Lung 198(4):705–714
Zhou X, Wu C, Cheng Q (2020) Negative lymph node count predicts survival of resected non-small cell lung cancer. Lung 198(5):839–846
Gazourian L, Durgana CS, Huntley D et al (2020) Quantitative pectoralis muscle area is associated with the development of lung cancer in a large lung cancer screening cohort. Lung 198(5):847–853
Albano D, Bilfinger T, Feraca M et al (2020) A multidisciplinary lung cancer program: does it reduce delay between diagnosis and treatment? Lung 198(6):967–972
Gowing S, Baker L, Tran A et al (2020) Postoperative adverse events are associated with oncologic recurrence following curative-intent resection for lung cancer. Lung 198(6):973–981
Horvath P, Lazar Z, Galffy G et al (2020) Circulating P-selectin glycoprotein ligand 1 and P-selectin levels in obstructive sleep apnea patients. Lung 198(1):173–179
Saoud M, Saeed M, Patel S et al (2020) Positive airway pressure adherence in patients with obstructive sleep apnea with schizophrenia. Lung 198(1):181–185
Kerget B, Afsin DE, Kerget F et al (2020) Is vimentin the cause or effect of obstructive sleep apnea development? Lung 198(2):275–282
Hirsch Allen AJ, Peres B, Ayas NT (2020) Obstructive sleep apnea severity and the risk of occupational injury: a prospective observational cohort. Lung 198(2):283–287
Sundar KM, Willis AM, Smith S et al (2020) A randomized, controlled, pilot study of CPAP for patients with chronic cough and obstructive sleep apnea. Lung 198(3):449–457
Peres BU, Hirsch Allen AJ, Kendzerska T et al (2020) Obstructive sleep apnea severity, body mass index, and circulating levels of cellular adhesion molecules. Lung 198(6):939–945
Rui P, Okeyode T (2019) National Ambulatory Medical Care Survey: 2016 national summary tables. https://www.cdc.gov/nchs/ahcd/ahcd_products.htm
Dicpinigaitis PV, Satia I, Ferguson N (2020) Falsely accused? Insufficient evidence to conclude that sitagliptin is a cause of chronic cough. Lung 198(2):271–273
Descazeaux M, Brouquières D, Didier A et al (2020) Obesity predicts treatment response to proton pump inhibitor therapy in patients with chronic cough. Lung 198(3):441–448
Abstracts from the Seventh American Cough Conference (2020) Lung 198(1):35–41
Hayes D Jr, Harhay MO, Nicol KK et al (2020) Lung T-cell profile alterations are associated with bronchiolitis obliterans syndrome in cystic fibrosis lung transplant recipients. Lung 198(1):157–161
Kwak SH, Lee SH, Park MS et al (2020) Risk factors for Cytomegalovirus reactivation in lung transplant recipients. Lung 198(5):829–838
May N, Niehaus-Gebele C, Reichenberger F et al (2020) Screening for bronchoscopic lung volume reduction: reasons for not receiving interventional treatment. Lung 198(1):221–228
Fiorelli A, Cascone R, Natale G et al (2020) Cardio-pulmonary changes after bronchoscopic lung volume reduction with endobronchial one-way valves. Lung 198(3):565–573
Van Dijk M, Klooster K, Hartman JE et al (2020) Change in dynamic hyperinflation after bronchoscopic lung volume reduction in patients with emphysema. Lung 198(5):795–801
Tan J, Chen H, He J et al (2020) Needle aspiration versus closed thoracostomy in the treatment of spontaneous pneumothorax: a meta-analysis. Lung 198(2):333–344
Husch HH, Watte G, Zanon M et al (2020) Effects of transcutaneous electrical nerve stimulation on pain, pulmonary function, and respiratory muscle strength after posterolateral thoracotomy: a randomized controlled trial. Lung 198(2):345–353
Ioachimescu OC, Stoller JK (2020) Area under the expiratory flow–volume curve (AEX): assessing bronchodilator responsiveness. Lung 198(3):471–480
Reyes A, Castillo A, Castillo J (2020) Effects of expiratory muscle training and air stacking on peak cough flow in individuals with Parkinson’s disease. Lung 198(1):207–211
Hill K, Ng LWC, Cecins N et al (2020) Effect of using a wheeled walker on physical activity and sedentary time in people with chronic obstructive pulmonary disease: a randomised cross-over trial. Lung 198(1):213–219
de Matto PM, Rodrigues Pereira G, Silva Barbosa M et al (2020) Association of Xpert MTB/RIF cycle threshold values with tuberculosis treatment outcomes. Lung 198(6):985–999
Eisenberg I, Yasin A, Fuks L et al (2020) Radiologic characteristics of non-tuberculous mycobacteria infection in patients with bronchiectasis. Lung 198(4):715–722
Weber J, Reeves AP, Doucette JT et al (2020) Quantitative CT evidence of airway inflammation in WTC workers and volunteers with low FVC spirometric pattern. Lung 198(3):555–563
Bersten AD, Krupa M, Griggs K et al (2020) Reduced surfactant contributes to increased lung stiffness induced by rapid inspiratory flow. Lung 198(1):43–52
Abe K, Horiguchi T, Enzan K et al (2020) Nicorandil, a KATP channel opener, attenuates ischemia–reperfusion injury in isolated rat lungs. Lung 198(2):315–321
Lian N, Zhang S, Huang J et al (2020) Resveratrol attenuates intermittent hypoxia-induced lung injury by activating the Nrf2/ARE pathway. Lung 198(2):323–331
Zou F, Su X, Pan P (2020) Toll-like receptor-4-mediated inflammation is involved in intermittent hypoxia-induced lung injury. Lung 198(5):855–862
Leuer L, Krill A, Wilkens H et al (2020) The phagocytosis of blood leukocytes from cystic fibrosis patients is not impaired in general. Lung 198(1):235–239
Youssef M, De Sanctis JB, Shah J et al (2020) Age-dependent progression in lung pathophysiology can be prevented by restoring fatty acid and ceramide imbalance in cystic fibrosis. Lung 198(3):459–469
Ritzenhaler JD, Zhang M, Torres-Gonzalez E et al (2020) The integrin inhibitor cilengitide and bleomycin-induced pulmonary fibrosis. Lung 198(6):947–955
Baer B, McCaig L, Yamashita C et al (2020) Exogenous surfactant as a pulmonary delivery vehicle for budesonide in vivo. Lung 198(6):909–916
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Peter Dicpinigaitis, MD, is the Editor-in-Chief of LUNG. No other conflicts of interest related to the content of this editorial.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Dicpinigaitis, P.V. LUNG Year in Review: 2020. Lung 199, 1–5 (2021). https://doi.org/10.1007/s00408-021-00418-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-021-00418-w